Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mirum Pharmaceuticals Inc (NQ: MIRM ) 41.03 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 9, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Mirum Pharmaceuticals Inc < Previous 1 2 3 4 5 6 7 8 9 Next > Mirum Pharma Out-Licenses Maralixibat Rights To GC Pharma in South Korea July 27, 2021 Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and GC Pharma have entered into an exclusive licensing agreement to develop and commercialize Mirum's maralixibat... Via Benzinga Mirum Pharmaceuticals and GC Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in South Korea July 26, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 12, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals to Present at Piper Sandler’s Virtual EASL Takeaway Day June 24, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Presents Analyses From Its Rare Liver Disease Programs at the EASL International Liver Congress 2021 June 23, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals to Showcase Analyses From Its Rare Liver Disease Programs at The International Liver Congress 2021 June 16, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 10, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D. to Board of Directors June 07, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Showcases Maralixibat Transplant-Free Survival Data for Progressive Familial Intrahepatic Cholestasis and Long-Term Safety Analyses for Alagille Syndrome during WCPGHAN Annual Meeting June 03, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the 6th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition (WCPGHAN) Annual Meeting 2021 May 26, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 10, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update May 06, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal May 01, 2021 CANbridge Pharma of Beijing acquired a global license to LogicBio’s adeno-associated virus sL65 in gene therapy candidates for Fabry and Pompe disease treatments. CANbridge will make a $10 million... Via Talk Markets Mirum Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021 April 29, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases April 29, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Receives Notice of Allowance for Methods of Use Patent for Maralixibat in Alagille Syndrome April 26, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 12, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis April 12, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.